NCT04646759: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have not received Herceptin/trastuzumab, chemotherapy, and/or endocrine (hormone) therapy; Patients with metastatic disease who have received more than first-line endocrine therapy, chemotherapy or targeted therapy; Patients with central nervous system metastasis & clinical symptoms

Comments are closed.

Up ↑